Filing Analysis
Health Catalyst, Inc. has appointed Steven Nelson, the current President of Aetna and former CEO of UnitedHealthcare, to its Board of Directors effective May 1, 2026. This appointment coincides with a temporary expansion of the board to seven members, which will return to six following the 2026 Annual Meeting as director Matthew Kolb is not standing for re-election.
Key Facts
- Steven Nelson appointed as a Class II director effective May 1, 2026.
- Board size increased from six to seven members to accommodate the appointment.
- Director Matthew Kolb will not stand for re-election at the 2026 Annual Meeting, at which point the board size will return to six.
- Steven Nelson currently serves as EVP and President of Aetna, Inc. (since November 2024).
- Nelson's previous experience includes CEO roles at ChenMed LLC, Duly Health and Care, and UnitedHealthcare (2017-2019).
Health Catalyst announced a 9% global workforce reduction and the elimination of approximately 100 open positions as part of a restructuring initiative called 'Project Nexus.' In connection with this restructuring, Linda Llewelyn will step down as Chief People Officer on June 1, 2026, and transition to a senior advisor role through September 2026.
Red Flags
- Significant workforce reduction (9%) suggests substantial cost-cutting pressure.
- Elimination of a C-suite role (Chief People Officer) rather than a simple replacement.
- Multiple 8-K items (5.02 and 8.01) filed simultaneously regarding restructuring.
Key Facts
- Board authorized a workforce reduction on April 24, 2026, as part of 'Project Nexus.'
- The reduction affects approximately 9% of the global workforce plus 100 open, budgeted positions.
- Chief People Officer Linda Llewelyn will depart effective June 1, 2026, due to the elimination of her role.
- Ms. Llewelyn will serve as a senior advisor from June 2, 2026, through September 1, 2026.
- The company expects the initiative to result in a 'meaningful reduction' in its cost structure.
Health Catalyst, Inc. finalized a transition agreement with former CEO Daniel Burton following his retirement on February 12, 2026. Mr. Burton will serve as a strategic advisor through December 31, 2026, receiving a monthly salary while forfeiting significant unvested equity awards.
Key Facts
- Transition Agreement signed on March 31, 2026, following Daniel Burton's retirement as CEO on February 12, 2026.
- Burton will serve as a strategic advisor until December 31, 2026.
- Compensation includes an average monthly base salary of $10,000 starting March 1, 2026.
- Burton will forfeit all unvested restricted stock units (RSUs) and performance-based RSUs (PSUs) eligible for vesting after March 2, 2026.
- The agreement includes a general release of claims against the Company.
Health Catalyst, Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. The disclosure was made via a press release furnished under Item 2.02 of Form 8-K.
Key Facts
- The report date and the date of the earliest event reported is March 12, 2026.
- The filing covers financial results for the quarter and fiscal year ended December 31, 2025.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition) and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Jason Alger, Chief Financial Officer, signed the filing.